DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy

Phase 2

Withdrawn

Conditions: Severe Aplastic Anemia (SAA)

Interventions: Drug: Romiplostim
Drug: Antithymocyte Globulin
Drug: Cyclosporine A

First Posted Date: 2022-04-12

Last Posted Date: 2023-09-29

Lead Sponsor: Amgen

Registration Number: NCT05323617

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

Phase 1

Recruiting

Conditions: Gastroesophageal Junction Cancer
Gastric Cancer

Interventions: Drug: Bemarituzumab
Drug: SOX
Drug: CAPOX
Drug: Nivolumab

First Posted Date: 2022-04-12

Last Posted Date: 2025-03-13

Lead Sponsor: Amgen

Target Recruit Count: 80

Registration Number: NCT05322577

Locations: 🇺🇸
Northport Veterans Affairs Medical Center, Northport, New York, United States
🇯🇵
Fujita Health University Hospital, Toyoake-shi, Aichi, Japan
🇯🇵
Hirosaki University Hospital, Hirosaki-shi, Aomori, Japan

and more 37 locations

A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

Phase 1

Terminated

Conditions: Non-squamous Non-small Cell Lung Cancer
Epithelial Ovarian Cancer
Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors

Interventions: Drug: AMG 794

First Posted Date: 2022-04-07

Last Posted Date: 2025-03-24

Lead Sponsor: Amgen

Target Recruit Count: 3

Registration Number: NCT05317078

Locations: 🇨🇭
Inselspital Bern, Bern, Switzerland
🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 5 locations

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Phase 4

Active, not recruiting

Conditions: Coronary Revascularization
Cardiovascular Disease
Myocardial Infarction
Stroke

Interventions: Drug: Routine Lipid Management
Drug: Evolocumab

First Posted Date: 2022-03-17

Last Posted Date: 2024-11-15

Lead Sponsor: Amgen

Target Recruit Count: 6019

Registration Number: NCT05284747

Locations: 🇺🇸
John Muir Health and Cardiovascular Institute, Concord, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Northern Arizona Healthcare Corporation Cardiovascular Institute, Flagstaff, Arizona, United States

and more 116 locations

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

Phase 1

Terminated

Conditions: Squamous-Cell Non-Small-Cell Lung Cancer

Interventions: Drug: Bemarituzumab
Drug: Docetaxel
Drug: Pembrolizumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Nab-paclitaxel

First Posted Date: 2022-03-04

Last Posted Date: 2025-03-25

Lead Sponsor: Amgen

Target Recruit Count: 74

Registration Number: NCT05267470

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳
Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan, Taiwan
🇺🇸
Montefiore Einstein Center for Cancer Care, Bronx, New York, United States

and more 36 locations

AMG 701 Expanded Access Program

First Posted Date: 2022-02-25

Last Posted Date: 2022-02-25

Lead Sponsor: Amgen

Registration Number: NCT05256446

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Phase 1

Terminated

Conditions: Higher Risk Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia

Interventions: Drug: AMG 176
Drug: Azacitidine

First Posted Date: 2022-01-26

Last Posted Date: 2025-02-14

Lead Sponsor: Amgen

Target Recruit Count: 7

Registration Number: NCT05209152

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

Phase 3

Active, not recruiting

Conditions: Colorectal Cancer (CRC)

Interventions: Drug: Trifluridine and Tipiracil
Drug: Sotorasib
Drug: Panitumumab
Drug: Regorafenib

First Posted Date: 2022-01-20

Last Posted Date: 2025-04-15

Lead Sponsor: Amgen

Target Recruit Count: 160

Registration Number: NCT05198934

Locations: 🇯🇵
Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan
🇺🇸
Kelsey Research Foundation, Houston, Texas, United States
🇺🇸
Northwest Georgia Oncology Centers PC, Marietta, Georgia, United States

and more 100 locations

Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)

Phase 3

Completed

Conditions: Palmoplantar Pustulosis

Interventions: Drug: Apremilast
Drug: Placebo

First Posted Date: 2021-12-30

Last Posted Date: 2025-04-09

Lead Sponsor: Amgen

Target Recruit Count: 176

Registration Number: NCT05174065

Locations: 🇯🇵
Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan
🇯🇵
Seibo International Catholic Hospital, Shinjuku-ku, Tokyo, Japan
🇯🇵
Medical corporation kojinkai Chitose dermatology and plastic surgery clinic, Chitose-shi, Hokkaido, Japan

and more 37 locations

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

Phase 3

Active, not recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Bemarituzumab
Drug: Nivolumab
Drug: Chemotherapy
Other: Placebo

First Posted Date: 2021-11-08

Last Posted Date: 2024-11-22

Lead Sponsor: Amgen

Target Recruit Count: 507

Registration Number: NCT05111626

Locations: 🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States
🇺🇸
University of Illinois Chicago, Chicago, Illinois, United States
🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

and more 347 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy